Japanese  
  Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Mayo Clinic: 2-drug Combination May… >
Mayo Clinic: 2-drug Combination May Slow Deadly Thyroid Cancer

Published: January 8, 2013.
By Mayo Clinic
http://www.mayoclinic.org/news

ROCHESTER, Minn. -- A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist.

Anaplastic thyroid cancer is a rare but devastating form of thyroid cancer that typically strikes men and women in their 60s and 70s. It is very aggressive, with a median survival of only about 5 months from time of diagnosis. Only 20 percent of patients survive a year beyond diagnosis, and it has historically been found to be resistant to most therapies.

Pazopanib, a kinase-inhibitor that interferes with the growth of cancer cells, is already approved by the Food and Drug Administration (FDA) to treat renal cancer tumors. Paclitaxel is an FDA-approved chemotherapy drug that disrupts the machinery involved in cell division.

Researchers studied anaplastic thyroid cancer cells and tumors in cell culture and in animal models. Human ATC cells were readily killed, and ATC tumors implanted into mice were 50 percent smaller when treated with the combination in comparison to the response to treatment with either drug alone. Pilot therapy of one patient with metastatic anaplastic thyroid cancer using the combination also resulted in marked tumor shrinkage lasting over six months. "This was a highly unexpected finding for this type of aggressive tumor, which often can double in size in a matter of days," Dr. Bible says.

In previous studies, pazopanib alone was found not effective in the treatment of anaplastic thyroid cancer. Paclitaxel was added to address the aggressiveness of anaplastic thyroid cancer tumors and bolster anti-cancer effects. The team investigated how the two drugs might complement each other.

Monitoring cancer cells multiply in time-lapse video under a microscope, researchers noted that the drug combination resulted in abnormal cell division and an increase in ATC cell death. Although pazopanib had not been known to specifically affect cell division, researchers speculated that the drug might have another unrecognized molecular target within cancer cells.

"We ended up learning that pazopanib also happens to inhibit a protein involved in cell division known as aurora A; this property seems to be involved in producing enhanced effects when pazopanib is combined with paclitaxel," Dr. Bible says. "This finding suggests that the combination may also be useful in treating other cancers, such as breast cancer, in which aurora A is sometimes found to be present in elevated amounts, as it is in ATC," Dr. Bible says.

The results also prompted an ongoing randomized multicenter clinical trial, led by Mayo Clinic and Memorial Sloan-Kettering Cancer Center and administered through the Radiation Therapy Oncology Group, testing the two-drug combination when added to radiation therapy in the initial treatment of patients with anaplastic thyroid cancer.

"This important next step is designed to determine whether the combination of drugs will improve ATC patient survival compared to paclitaxel alone," Dr. Bible says.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
This is form to send feedback to the editors. Tell us what you think about this article. All comments are not published. If you are looking for a response to a question please use our another feedback page.
Related »

Drugs 
2/7/12 
3 'Targeted' Cancer Drugs Raise Risk of Fatal Side Effects
By Dana-Farber Cancer Institute
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at …
Sunitinib 
8/21/13 
Pazopanib Shows Better Quality-of-life in Advanced Kidney Cancer
By Dana-Farber Cancer Institute
BOSTON -- Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial …
Kinase 
11/1/13 
Double-pronged Attack Could Treat Common Children's Cancer
By Institute of Cancer Research
A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become …
Cancer 
3/28/12 

Map of Substrate-kinase Interactions May Lead to More Effective Cancer Drugs
By Purdue University
Survival 
11/5/13 
★★★ 
Drug Combination Therapy Causes Cancer Cells to 'Eat Themselves'
By Virginia Commonwealth University
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, …
Patients 
6/28/11 
Patients Treated with Sunitinib And Sorafenib Respond to Flu Vaccine
By American Association for Cancer Research
PHILADELPHIA — Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according …
Cells 
10/1/12 
★ 
Breakthrough in Understanding Lung Cancer Vulnerabilities Points the Way to New Targeted Therapy
By University of Sheffield
More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study. Scientists from the Universities …
Cancer 
10/1/12 
New Weapons in the Fight Against Cancer
By European Society for Medical Oncology
VIENNA, Austria, 30 September 2012 – Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society …
Pathways 
1/16/13 
Pandemic Vaccination Did Not Increase Risk of Fetal Death
By Norwegian Institute of Public Health
With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment …
More » 
 
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.